logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
S

Seock‐Ah Im

seoul national university

98H-index
1.1KPaper Count
6.9WCitation Count
Published Papers 387
Publication Date
logo
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study
errESMO Open
IF8.3
err2026-07-24
err0
errOAAI
errH.S. Rugo; K. Jhaveri; S. Pernas; B. Pistilli; S.-A. Im; M. De Laurentiis; S. Wang; N. Martínez Jañez; G. Borges; D.W. Cescon; M. Hattori; Y.-S. Lu; E. Hamilton; Q. Zhang; J. Tsurutani; K. Kalinsky; P.E. Rubini Liedke; Z. Nowecki; S.M. Tolaney; K. Zhao
errShare
errSave
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
errLancet Oncology
IF35.9
err2026-07-13
err0
PREAI
errNicholas C Turner; Erica L Mayer; Yeon Hee Park; Wolfgang Janni; Cynthia Ma; Massimo Cristofanilli; Giampaolo Bianchini; Kevin Kalinsky; Hiroji Iwata; Stephen Chia; Adam M Brufsky; Peter A Fasching; Zbigniew Nowecki; Javier Pascual; Nuri Karadurmus; Einav Gal-Yam; Wei-Pang Chung; Seock-Ah Im; Alberto Zambelli; Florence Dalenc
errShare
errSave
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial
errNature Cancer
IF28.5
err2026-06-08
err0
errOAAI
errPeter Schmid; Seock-Ah Im; Zbigniew Nowecki; Piotr J. Wysocki; Jacek Jassem; Kyung Hae Jung; Simon Lord; Jon Armstrong; Ross Stewart; Petra Vuković; Neelima Denduluri; Yeon Hee Park
errShare
errSave
Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer
errESMO Open
IF8.3
err2026-05-27
err0
errOAAI
errS.-A. Im; K. Kalinsky; K.L. Jhaveri; S. Loibl; N. Turner; C. Saura; P. Schmid; S. Loi; E. Hamilton; N. Karadurmus; S. Wang; A.A. Awan; E.M. Ciruelos; C.-F. Chung; E. Thanopoulou; N. Shankar; S. Lim; Y. Jin; C. Song; D. Juric
errShare
errSave
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC
errBritish Journal of Cancer
IF6.8
err2026-03-31
err0
errOAAI
errJuanita S. Lopez; Kevin J. Harrington; Seock-Ah Im; Keun-Wook Lee; Sophie Postel-Vinay; Jacob S. Thomas; Natalia Lukashchuk; Sophie E. Willis; Itziar Irurzun-Arana; Benjamin Webb; Jyoti Nehra; Alan Lau; Arsène-Bienvenu Loembé; Emma Dean; Matthew G. Krebs
errShare
errSave
Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer
errBritish Journal of Cancer
IF6.8
err2026-03-27
err0
PREAI
errYoonjin Kwak; Tae-Yong Kim; Hye Seung Lee; Soo Kyung Nam; Hyeon Jeong Oh; Do-Youn Oh; Seock-Ah Im
errShare
errSave
Phase II trial, multicenter, first-line paclitaxel-avelumab treatment of inoperable angiosarcoma (KCSG UN 18-15)☆
errESMO Open
IF8.3
err2026-01-22
err0
errOAAI
errH.R. Kim; M. Kim; M.J. Kang; J.E. Kim; Y.J. Kim; K. Park; W.K. Bae; M.-W. Lee; J.-Y. Hong; Y.S. Kim; S.-A. Im; J. Lee; S.Y. Oh
errShare
errSave
Cancer Manipulates Adjacent Adipose Tissue to Exploit Fatty Acids via HIF-1α/CCL2/PPARα Axis: A Metabolic Circuit to Support Tumor Progression
errAdvanced Science
IF14.1
err2025-10-29
err0
errOAAI
errJeong-Eun Yun; Jieun Seo; Jiwon Koh; Seock-Ah Im; Ki Yong Hong; Yeseon Son; Do-Won Jeong; Junji Fukuda; Jong-Wan Park; Yang-Sook Chun
errShare
errSave
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival☆
errESMO Open
IF8.3
err2025-10-17
err0
errOAAI
errJ. Crown; D. Stroyakovskii; D.A. Yardley; C.-S. Huang; P.A. Fasching; A. Bardia; S. Chia; S.-A. Im; M. Martin; B. Xu; C.H. Barrios; M. Untch; R. Moroose; S.A. Hurvitz; G.N. Hortobagyi; D.J. Slamon; F. Visco; G. Spera; J.P. Zarate; D. Halligan; Z. Li; S. Loi
errShare
errSave
Longitudinal trajectory of menopausal symptoms in premenopausal women throughout adjuvant chemotherapy: a two-stage analytical approach
errSupportive Care in Cancer
IF3
err2025-10-14
err0
PREAI
errSaim Jung; Jaehyun Kim; Sun Hyung Lee; Joon Sung Shin; Won-Hyoung Kim; Dooyoung Jung; Tae-Yong Kim; Seock-Ah Im; Kyung-Hun Lee; Bong-Jin Hahm; Chan-Woo Yeom
errShare
errSave
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
errNature Medicine
IF50
err2025-10-08
err0
errOAAI
errShanu Modi; William Jacot; Hiroji Iwata; Yeon Hee Park; Maria Vidal Losada; Wei Li; Junji Tsurutani; Naoto T. Ueno; Khalil Zaman; Aleix Prat; Konstantinos Papazisis; Hope S. Rugo; Toshinari Yamashita; Nadia Harbeck; Seock-Ah Im; Michelino De Laurentiis; Jean-Yves Pierga; Xiaojia Wang; Andrea Gombos; Eriko Tokunaga; Cecilia Orbegoso Aguilar; Lotus Yung; Feng Xiao; Yingkai Cheng; David Cameron
errShare
errSave
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy
errnpj Breast Cancer
IF7.6
err2025-10-02
err0
errOAAI
errJavier Cortes; Oleg Lipatov; Seock-Ah Im; Anthony Goncalves; Keun Seok Lee; Peter Schmid; Kenji Tamura; Laura Testa; Shoichiro Ohtani; Nadia Harbeck; Sherene Loi; Roberto Salgado; Vassiliki Karantza; Jaime Mejia; Razvan Cristescu; Andrey Loboda; Michael Nebozhyn; Petar Jelinic; Lingkang Huang; Eric P. Winer
errShare
errSave
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)
errESMO Open
IF8.3
err2025-09-24
err0
PREAI
errS.-A. Im; K. Park; J. Koh; C. Park; K.H. Jung; J. Lee; H.K. Ahn; A. Lee; S.H. Sim; M.H. Kim; J.H. Kim; J.H. Kim; K.E. Lee; K.H. Park; J. Bae; M.H. Lee; S. Lim; H.J. Kim; D.-W. Lee; J.H. Jeong; K.S. Lee; J. Sohn; K.J. Suh; J.-Y. Kim; Y.J. Cha; J. Moon; C.-Y. Ock; S.-B. Kim; K. Shin; H. Chae; G.M. Kim; K.-H. Lee; W.-Y. Park; Y.H. Park; I.H. Park
errShare
errSave
Establishment and characterization of 24 breast cancer cell lines and 3 breast cancer organoids reveals molecular heterogeneity and drug response variability in malignant pleural effusion-derived models
errBREAST CANCER RESEARCH
IF5.6
err2025-05-01
err0
errOAAI
errKim, Soon-Chan; Kim, Ga-Hye; Park, Jae-Hyeon; Lee, Kyung-Hun; Koh, Jiwon; Kim, Tae-Yong; Lee, Dae-Won; Kim, Yu-Jin; Kim, Seongyeong; Park, Song-Yi; Min, Ahrum; Shin, Young-Kyoung; Im, Seock-Ah; Ku, Ja-Lok
errShare
errSave
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
errBREAST CANCER RESEARCH
IF5.6
err2025-03-11
err0
errOAAI
errDent, Rebecca; Cortes, Javier; Park, Yeon Hee; Munoz-Couselo, Eva; Kim, Sung-Bae; Sohn, Joohyuk; Im, Seock-Ah; Holgado, Esther; Foukakis, Theodoros; Kuemmel, Sherko; Yearley, Jennifer; Wang, Anran; Nebozhyn, Michael; Huang, Lingkang; Cristescu, Razvan; Jelinic, Petar; Karantza, Vassiliki; Schmid, Peter
errShare
errSave
Pathologic Features of Early-Stage Triple-Negative Breast Cancer Treated with Neoadjuvant Pembrolizumab Plus Chemotherapy
errLABORATORY INVESTIGATION
IF4.2
err2025-03-01
err0
PREAI
errKoh, Jiwon; Kim, Jee; Park, Hyeyeon; Kwon, Hyun Jung; Ryu, Han Suk; Kim, Jung Ho; Koh, Jaemoon; Lee, Kyung-Hun; Lee, Dae-Won; Park, Changhee; Im, Seock-Ah; Seo, Jeongmin; Kim, Jee Hyun; Park, So Yeon
errShare
errSave
Updated efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate, in heavily pretreated advanced solid tumors with HER2-expression or mutations: a global, multicenter, phase 1 study
errBREAST
IF7.9
err2025-02-01
err0
errOAAI
errYao, H.; Yan, M.; Tong, Z.; Wu, X.; Yin, Y.; Ryu, M. -h.; Park, J. J.; Dai, T.; Zhao, Y.; Kim, J. H.; Wang, S.; Zhong, Y.; Voskoboynik, M.; Zhang, J.; Kaubisch, A.; Liu, C.; Chen, Y.; Im, S. -a.; Wu, L.; Liu, Y.; Ganju, V.; Barve, M.; Li, H.; Yao, G.; Bao, L.; Teng, Y.; Qian, J.; Zhou, H.; Zhao, J.; Zhao, K.; Shen, Y.; Rong, S.; Zhu, X.; Song, E.
errShare
errSave
Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer
errESMO OPEN
IF8.3
err2024-12-01
err1
PREAI
errKim, T. Y.; Kwak, Y.; Nam, S. K.; Han, D.; Oh, D. Y.; Im, S. A.; Lee, H. S.
errShare
errSave
Immune marker expression and prognosis of early breast cancer expressing HER3
errEUROPEAN JOURNAL OF CANCER
IF7.1
err2024-12-01
err0
PREAI
errLee, Dae-Won; Ryu, Han Suk; Nikas, Ilias P.; Koh, Jiwon; Kim, Tae-Yong; Kim, Hong Kyu; Lee, Han-Byoel; Moon, Hyeong-Gon; Han, Wonshik; Lee, Kyung-Hun; Im, Seock-Ah
errShare
errSave
Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy
errBREAST CANCER RESEARCH
IF5.6
err2024-11-05
err0
errOAAI
errLee, Young Joo; Noh, Woo Chul; Gwark, Sungchan; Kim, Hyun-Ah; Ryu, Jai Min; Kim, Seung Il; Lee, Eun-Gyeong; Im, Seock-Ah; Jung, Yongsik; Park, Min Ho; Park, Kyong Hwa; Kang, Su Hwan; Jeong, Joon; Park, Eunhwa; Kim, Sung Yong; Lee, Min Hyuk; Kim, Lee Su; Lim, Woosung; Kim, Seonok; Kim, Hee Jeong
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
G
Gabriel N. Hortobágyi
H-index: 187 · Papers: 1.9K
E
Eric P. Winer
H-index: 170 · Papers: 1.6K
M
Mien‐Chie Hung
H-index: 163 · Papers: 1.5K
F
Fabrice André
H-index: 148 · Papers: 1.8K
J
Josep Tabernero
H-index: 146 · Papers: 2.7K
View more